Supplementary Fig. S1 Comparison of venous thromboembolism (VTE) between the rivaroxaban group and the aspirin group (funnel plot). RR, risk ratio.

Supplementary Fig. S2 Comparison of venous thromboembolism (VTE) between the rivaroxaban group and the aspirin group (cumulative meta-analysis). RR, risk ratio.
Supplementary Fig. S3 Comparison of venous thromboembolism (VTE) between the rivaroxaban group and the aspirin group in subgroup analysis (administration with 10 and 20 mg rivaroxaban). RR, risk ratio.
Supplementary Fig. S4 Comparison of venous thromboembolism (VTE) between the rivaroxaban group and the aspirin group in subgroup analysis (administration with 100 mg and other aspirin). RR, risk ratio.
Supplementary Fig. S5 Comparison of venous thromboembolism (VTE) between the rivaroxaban group and the aspirin group in subgroup analysis (reception of total hip arthroplasty [THA], total knee arthroplasty [TKA], and other surgery). RR, risk ratio.
Supplementary Fig. S6 Comparison of venous thromboembolism (VTE) between the rivaroxaban group and the aspirin group in subgroup analysis (medication duration less than 2, 2, 4, and more than 4 weeks). RR, risk ratio.
Supplementary Fig. S7 Comparison of venous thromboembolism (VTE) between the rivaroxaban group and the aspirin group in subgroup analysis (follow-up time less than 1, 1, 3, and 12 months). RR, risk ratio.
Supplementary Fig. S8 Comparison of venous thromboembolism (VTE) between the rivaroxaban group and the aspirin group in subgroup analysis (from China and Canada). RR, risk ratio.